



Effect of the Sodium-Glucose Cotransporter 2 Inhibitor Canagliflozin for Heart Failure With Preserved Ejection Fraction in Patients With Type 2 Diabetes

Tomoya Ueda, MD, PhD; Shu Kasama, MD, PhD; Masahiro Yamamoto, MD, PhD;
Tomoya Nakano, MD, PhD; Kazuhiro Ueshima, MD; Yoshinobu Morikawa, MD, PhD;
Hiroyuki Kawata, MD, PhD; Akiomi Yoshihisa, MD, PhD; Masafumi Nakayama, MD, PhD;
Sei Komatsu, MD, PhD; Tsunenari Soeda, MD, PhD; Makoto Watanabe, MD, PhD;
Rika Kawakami, MD, PhD; Yasushi Okada, BSc; Hiroyuki Tanaka, BSc; Yutaka Susuta, PhD;
Masato Kasahara, MD, PhD; Kenichi Tsujita, MD, PhD; Yasuchika Takeishi, MD, PhD;
Yoshihiko Saito, MD, PhD; CANONICAL Study Group

Supplementary Table 1. Body Weight and Plasma BNP Levels at 4, 12, and 24 Weeks After Treatment

	CAN (n=42)	STDT (n=40)	P value
Body weight, kg			
Baseline	62.89±10.96	63.90±11.38	0.6853
4 weeks	61.43±10.85	64.26±11.17	0.2538
12 weeks	62.11±10.65	63.34±11.22	0.4464
24 weeks	61.07±10.99	63.08±11.47	0.3398
Plasma BNP, pg/mL			
Baseline	134 (75–213)	130 (93-219)	0.5186
4 weeks	98 (57-215)	144 (93-239)	0.0522
12 weeks	97 (54-214)	137 (99-219)	0.1660
24 weeks	102 (58-206)	160 (85-249)	0.2828

Body weight and Plasma BNP data are shown as the mean ± standard deviation and median (25th-75th percentile), respectively.

BNP, B-type natriuretic peptide.

Supplementary Table 2. Systolic Blood Pressure, Diastolic Blood Pressure and Heart Rate at 4, 12, and 24 Weeks After Treatment

	CAN (n=42)	STDT (n=40)	P value
Systolic blood pressure, mmHg			
Baseline	131.1±14.6	131.5±16.2	0.9109
4 weeks	130.8±15.3	128.3±15.2	0.4660
12 weeks	126.3±17.5	126.3±16.6	0.9910
24 weeks	126.0±14.7	127.9±17.1	0.5940
Diastolic blood pressure, mmHg			
Baseline	71.6±12.1	70.0±10.5	0.2959
4 weeks	71.4±10.0	66.8±12.2	0.0650
12 weeks	70.9±12.2	66.7±13.3	0.1589
24 weeks	70.4±11.8	68.2±12.4	0.4154
Heart rate, beats/minute			
Baseline	70.5±11.0	67.4±10.9	0.1996
4 weeks	71.5±11.9	67.6±10.9	0.1285
12 weeks	71.3±17.3	66.0±10.1	0.1056
24 weeks	72.0±12.5	66.9±10.2	0.0558

Data are shown as the mean ± standard deviation.

CANONICAL Study Group Member

Nara Medical University

Tomoya Ueda, Yoshihiko Saito, Kazutaka Nogi, Azusa Sakagami, Hiroki Yano, Yasuki Nakata, Yukihiro Hashimoto, Akihiro Takitsume, Hitoshi Nakagawa, Taku Nishida, Kenji Onoue, Tsunenari Soeda, Makoto Watanabe, Rika Kawakami.

Graduate School of Medical Sciences, Kumamoto University

Masahiro Yamamoto, Kenichi Tsujita

Yamato Takada Municipal Hospital

Tomoya Nakano, Kazuhiro Ueshima

Minami-Nara General Medical Center

Yoshinobu Morikawa

Nara Prefecture General Medical Center

Takuya Nakamura, Hiroyuki Kawata

Fukushima Medical University

Akiomi Yoshihisa, Yasuchika Takeishi

Nakayama Cardiovascular Clinic

Masafumi Nakayama

Osaka Gyomeikan Hospital

Sei Komatsu

National Cerebral and Cardiovascular Center

Hiroyuki Takahama, Satoshi Yasuda

Hyogo College of Medicine College

Masanori Asakura

Osaka University

Tomohito Ohtani, Yasushi Sakata

Nara Prefecture Seiwa Medical Center

Takehito Nakai, Naofumi Doi

Shinshu University

Hirohiko Motoki, Koichiro Kuwahara

Tottori University Hospital

Kazuhiro Yamamoto

Gunma University Hospital

Noriaki Takama

Rakuwakai Marutamachi Hospital

Ichiro Hamanaka

Nara City Hospital

Manabu Horii

Hiramitsu Heart Clinic

Shinya Hiramitsu

Onishi Heart Clinic

Katsuya Onishi

Clinic Jingu-mae

Takeshi Takami